We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

A. Menarini Diagnostics S.r.l.

A. Menarini Diagnostics S.r.l. is fully committed to developing high tech diagnostics instruments and reagents to imp... read more Featured Products: More products

Download Mobile App




Innovative All-in-One MDx Platform Addresses Needs of Medium-to-High Throughput Laboratories

By LabMedica International staff writers
Posted on 23 May 2023

The COVID-19 pandemic has brought significant changes to the molecular diagnostics market, driving it towards automation, user-friendliness, quick results, and reliability of tests. More...

Despite remarkable progress in this field, many testing applications still depend on lab-developed tests and labor-intensive methods, which complicate the execution of large-scale automated diagnostics solutions. To address these challenges and market trends, a new all-in-one, fully automated molecular diagnostics platform is now available for the processing of various testing portfolios through real-time PCR.

Menarini Diagnostics (Florence, Italy) has launched its PRIME MDx system which allows users to handle various sample types by cleverly utilizing pre-filled plates along with a universal extraction solution. It can run up to five different assays per sample, reaching a maximum capacity of 240 samples per day. The system's continuous workflow feature allows users to initiate a new loading process (extraction/setup) even while a previous PCR is still running. Its AI-driven software guarantees a smooth user experience, from uninterrupted sample loading to result interpretation, resulting in high-quality results, standardized workflows, and enhanced lab efficiency. PRIME MDx's automation and guided instrument setup minimize manual intervention and guarantee full sample traceability.

PRIME MDx offers the flexibility to manage runs with various extraction reagent formats (prefilled or standard) and seamlessly integrates with the existing IT infrastructure. This fully automated sample-to-result system is specifically engineered to simplify laboratory workflows for real-time PCR diagnostic assays, delivering outstanding efficiency, flexibility, and user-friendliness. The system is being introduced with two test panels, one for viral upper respiratory tract infections and another for viral transplant infections, applicable to a broad spectrum of sample matrices. Additional test panels are currently in the development phase to broaden the offerings.

"We are proud to bring this innovative, all-in-one, molecular diagnostics solution to the market, which will allow us to address the needs of medium-to-high throughput laboratories internationally and strengthen the position of A. Menarini Diagnostics in the molecular space," said Fabio Piazzalunga, General Manager and Global Head of Diagnostics Division in Menarini Group.

Related Links:
Menarini Diagnostics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
All-in-One Molecular System
AIO M160
New
Automated Immunoassay Analyzer
SuperFlex™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.